Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247–1251
Abstract
Recently, Mone et al. (1) reported that the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin improves cognitive and physical impairment in frail older adults with diabetes and heart failure with preserved ejection fraction (HFpEF).The latest guideline from the American Heart Association, American College of Cardiology, and Heart Failure Society of America (2) recommends, in patients with heart failure and type 2 diabetes, the use of SGLT2i for the management of hyperglycemia and to reduce heart failure-related morbidity and mortality.The guideline also states that in patients with HFpEF, SGLT2i can be beneficial in decreasing heart failure hospitalizations and cardiovascular mortality.EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) enrolled 5,988 patients with HFpEF with and without type 2 diabetes.The primary outcome was hospitalization for heart
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.